Research Article Cites Cleanascite™ for Bead-based Antibody Array Proteome Analysis of Human Bile

April 6, 2010

News Release

Research Article Cites Cleanascite™ for Bead-based Antibody Array Proteome Analysis of Human Bile

MONMOUTH JUNCTION, NJ, February 22, 2017 -- Biotech Support Group reports on a recent research article describing the simplicity and efficiency of their lipid clearance sample preparation technology for bile fluid.

The citation is:

Vesterhus, Mette, et al. "Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis." Journal of Hepatology (2017).

In brief, the article’s authors aimed to identify novel protein biomarkers of disease severity and prognosis in primary sclerosing cholangitis (PSC). They analyzed bile samples using a bead-based array targeting 63 proteins. The article states “The samples were thawed and 100 μL of bile was added to 150 μL PBS containing 0.1% Tween 20 and Protease Inhibitor Cocktail (Sigma-Aldrich, St. Louis, Missouri, USA), then centrifuged at 4 °C for 10 minutes at 14000 rpm. CleanAscite™ (100 μL, Biotech Support Group, NJ, USA)…”. The authors identified novel biliary and serum biomarkers of severity and prognosis in PSC.

This reference shows the versatility of Cleanascite™ to efficiently remove lipids from bile fluid, with a selectivity profile suitable for proteome analysis using antibody-based arrays.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to

Matthew Kuruc 732-274-2866